CNCR:NSD-Loncar Cancer Immunotherapy ETF (USD)

ETF | Health |

Last Closing

USD 13.39

Change

-0.86 (-6.05)%

Market Cap

USD 0.01B

Volume

5.62K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The index was established in 2023 by Range Fund Holdings and tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts ("ADRs") with a market capitalization of more than $250 million. The advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. Under normal circumstances, at least 80% of the fund"s total assets will be invested in the component securities of the index.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-15 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
IBB iShares Biotechnology ETF

-6.71 (-4.79%)

USD 7.19B
PPH VanEck Pharmaceutical ETF

-1.58 (-1.79%)

USD 0.67B
BBH VanEck Biotech ETF

-7.22 (-4.37%)

USD 0.43B
PSCH Invesco S&P SmallCap Health Ca..

-0.99 (-2.18%)

USD 0.18B
PTH Invesco DWA Healthcare Momentu..

-1.69 (-3.72%)

USD 0.14B
GNOM Global X Genomics & Biotechnol..

-0.55 (-5.39%)

USD 0.08B
FTXH First Trust Nasdaq Pharmaceuti..

-0.89 (-3.18%)

USD 0.02B

ETFs Containing CNCR

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.59% 50% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.59% 50% F 45% F
Trailing 12 Months  
Capital Gain 25.73% 88% B+ 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.73% 88% B+ 69% C-
Trailing 5 Years  
Capital Gain -37.17% 13% F 32% F
Dividend Return 10.05% 86% B+ 33% F
Total Return -27.13% 25% F 32% F
Average Annual (5 Year Horizon)  
Capital Gain -6.41% 13% F 25% F
Dividend Return -4.59% 13% F 27% F
Total Return 1.82% 100% F 45% F
Risk Return Profile  
Volatility (Standard Deviation) 31.54% 38% F 59% D-
Risk Adjusted Return -14.56% 13% F 27% F
Market Capitalization 0.01B 13% F 15% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.